Posts

FDA disputes Capricor's claims of Phase 3 success for DMD cell therapy, deramiocel

on

Capricor Shares Plunge After FDA Says DMD Therapy Lacks Efficacy Ahead of Advisory Committee Meeting

on

Capricor Claims FDA Misinterpreted Efficacy Data Leading to Rejection of DMD Therapy

on

FDA Rejects Capricor's Cell Therapy for Duchenne Muscular Dystrophy

on

Capricor shares turn red as FDA plans deramiocel adcomm, likely the first under new commissioner

on